Neeraj K Aryal
Overview
Explore the profile of Neeraj K Aryal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Portelinha A, Wang S, Parsa S, Jiang M, Gorelick A, Mohanty S, et al.
J Exp Med
. 2024 Sep;
221(10).
PMID: 39235528
The translocation t(14;18) activates BCL2 and is considered the initiating genetic lesion in most follicular lymphomas (FL). Surprisingly, FL patients fail to respond to the BCL2 inhibitor, Venetoclax. We show...
2.
Pant V, Aryal N, Xiong S, Chau G, Fowlkes N, Lozano G
Cancer Res
. 2022 Jan;
82(7):1313-1320.
PMID: 35078816
Significance: This in vivo study highlights that alterations to the C-terminus of Mdm2 perturb its regulation of the tumor suppressor p53.
3.
Wasylishen A, Sun C, Moyer S, Qi Y, Chau G, Aryal N, et al.
Sci Adv
. 2020 Aug;
6(32):eaba8415.
PMID: 32821827
Tumor sequencing studies have emphasized the role of epigenetics and altered chromatin homeostasis in cancer. Mutations in , which encodes a chaperone for the histone 3.3 variant, occur in 25%...
4.
Aryal N, Parker-Thornburg J
Methods Mol Biol
. 2019 Sep;
2066:133-148.
PMID: 31512214
Prior to generating a new mouse model, it is important to plan the method that will be used to detect which of the mice generated have the mutation(s) desired. Nearly,...
5.
Pant V, Xiong S, Wasylishen A, Larsson C, Aryal N, Chau G, et al.
Proc Natl Acad Sci U S A
. 2019 Aug;
116(35):17429-17437.
PMID: 31409715
Gastrointestinal (GI) syndrome is a serious side effect and dose-limiting toxicity observed in patients undergoing lower-abdominal radiotherapy. Previous mouse studies show that gene dosage determines susceptibility to GI syndrome development....
6.
Aryal N, Pant V, Wasylishen A, Rimel B, Baseler L, El-Naggar A, et al.
Cancer Res
. 2019 Mar;
79(10):2662-2668.
PMID: 30914430
functions as a tumor suppressor in mouse models. In humans, somatic mutations are associated with many cancers in adults, and patients with DICER1 syndrome with germline mutations are susceptible to...
7.
Aryal N, Pant V, Wasylishen A, Parker-Thornburg J, Baseler L, El-Naggar A, et al.
Proc Natl Acad Sci U S A
. 2018 Dec;
116(3):960-969.
PMID: 30593561
gene alterations and decreased expression are associated with developmental disorders and diseases in humans. Oscillation of Dicer1 phosphorylation and dephosphorylation regulates its function during the oocyte-to-embryo transition in Dicer1 is...
8.
Aryal N, Wasylishen A, Lozano G
Cell Death Dis
. 2018 Oct;
9(11):1099.
PMID: 30368519
No abstract available.
9.
Aryal N, Wasylishen A, Pant V, Riley-Croce M, Lozano G
Oncotarget
. 2017 Dec;
8(61):103996-104006.
PMID: 29262616
Increased levels of inhibitors of the p53 tumor suppressor such as Mdm2 and Mdm4 drive tumor development and thus serve as targets for therapeutic intervention. Recently, digestive organ expansion factor...
10.
Xiong S, Pant V, Zhang Y, Aryal N, You M, Kusewitt D, et al.
J Pathol
. 2016 Dec;
241(4):501-510.
PMID: 27925213
The p53 inhibitor Mdm4 is present at high levels in multiple human cancers. Overexpression of Mdm4 in mice drives the spontaneous development of mostly lymphomas and sarcomas. In this study,...